Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Epidemiology of colorectal cancer in Guangzhou, China: A cross-sectional and age-period-cohort study.

PLOS global public health·2026
Same author

Bimetallic Ni<sub>3</sub>Fe/Ni<sub>2</sub>Fe<sub>2</sub>N Catalyst With Optimized d-Band Center for High-Efficiency Lithium-Sulfur Batteries.

Angewandte Chemie (International ed. in English)·2026
Same author

Pediatric-onset spinocerebellar ataxia type 3 with dual <i>ATXN3</i> and <i>HTT</i> gene mutations: a case report and literature-informed hypothesis.

Frontiers in genetics·2026
Same author

Analysis of the current situation and influencing factors of dyslipidemia among adults in Guangzhou based on a cross-sectional survey.

Medicine·2026
Same author

Estimated incidence of influenza in Guangzhou, China, 2019-2022.

Infectious medicine·2026
Same author

Senecavirus a VP2 protein orchestrates PRDX1 degradation through dual autophagy pathways: macroautophagy and chaperone-mediated autophagy.

Autophagy·2026

Related Experiment Video

Updated: May 8, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

GLUT1 rs1385129G>A Raised the Risk and Poor Prognosis of Lung Cancer: A Case-Control Study.

Zhi Li1, Dedong Wang1,2, Jinbin Chen1

  • 1The State Key Lab of Respiratory Disease, The First Affiliated Hospital, The Institute for Chemical Carcinogenesis, School of Public Health, Guangzhou Medical University, Guangzhou, Guangdong, China, gzhmc.edu.cn.

Human Mutation
|May 7, 2026
PubMed
Summary

Genetic variations in the glucose transporter 1 (GLUT1) gene, specifically rs1385129G>A, are linked to an increased risk of lung cancer (LC). This GLUT1 variant also correlates with poorer prognosis in LC patients due to elevated GLUT1 expression.

Keywords:
glucose transporter 1glycolyticlung cancerrs1385129single nucleotide polymorphism

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Related Experiment Videos

Last Updated: May 8, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Area of Science:

  • Oncology
  • Genetics
  • Cancer Metabolism

Background:

  • Altered cancer cell energy metabolism, particularly abnormal glycolysis, is a promising therapeutic target.
  • Evidence linking genetic variations in glycolysis genes to lung cancer (LC) risk and progression is limited.
  • This study investigates the impact of glycolytic pathway-related gene variations on LC development.

Purpose of the Study:

  • To clarify the genetic effect of glycolytic pathway-related genes on the occurrence and development of LC.
  • To evaluate the association between specific genetic variations in glycolysis genes and LC risk.
  • To assess the relationship between GLUT1 rs1385129G>A, GLUT1 expression, and LC clinical progression.

Main Methods:

  • A two-stage case-control study involving 300 LC patients and 600 healthy controls, plus 1248 case-control pairs.
  • Genotyping of glycolysis-related genes: GLUT1 rs1385129G>A, GLUT11 rs6003939A>C, GLUT12 rs1484180G>A, and ENO2 rs11064467C>T.
  • Analysis of follow-up data, TCGA database, GTEx database (eQTL), GEPIA, and Kaplan-Meier Plotter for gene expression and survival.

Main Results:

  • The GLUT1 rs1385129G>A variant was significantly associated with an increased risk of LC (p < 0.05).
  • GLUT1 expression levels were positively correlated with the number of A alleles at rs1385129 (p < 0.01), with stronger effects for GA and AA genotypes.
  • The GA and AA genotypes of GLUT1 rs1385129 were linked to a worse prognosis in LC patients (HR = 1.37), and high GLUT1 expression correlated with increased risk of poor survival.

Conclusions:

  • The GLUT1 rs1385129G>A polymorphism may increase lung cancer risk.
  • This genetic variation potentially contributes to poor prognosis in lung cancer by upregulating GLUT1 expression.
  • Targeting GLUT1-mediated glycolysis could be a strategy for lung cancer therapy.